Cargando…

The phosphoinositide-3 kinase (PI3K)-δ,γ inhibitor, duvelisib shows preclinical synergy with multiple targeted therapies in hematologic malignancies

Duvelisib is an orally active dual inhibitor of PI3K-δ and PI3K-γ in clinical development in hematologic malignancies (HM). To identify novel pairings for duvelisib in HM, it was evaluated alone and in combination with 35 compounds comprising a diverse panel of standard-of-care agents and emerging d...

Descripción completa

Detalles Bibliográficos
Autores principales:	Faia, Kerrie, White, Kerry, Murphy, Erin, Proctor, Jennifer, Pink, Melissa, Kosmider, Nicole, McGovern, Karen, Kutok, Jeffery
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2018
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6070190/ https://www.ncbi.nlm.nih.gov/pubmed/30067771 http://dx.doi.org/10.1371/journal.pone.0200725

Ejemplares similares

Duvelisib: A 2018 Novel FDA-Approved Small Molecule Inhibiting Phosphoinositide 3-Kinases
por: Rodrigues, Daniel A., et al.
Publicado: (2019)

Impact of the Smoothened Inhibitor, IPI-926, on Smoothened Ciliary Localization and Hedgehog Pathway Activity
por: Peluso, Marisa O., et al.
Publicado: (2014)

Roles of PI3Kγ and PI3Kδ in mantle cell lymphoma proliferation and migration contributing to efficacy of the PI3Kγ/δ inhibitor duvelisib
por: Till, Kathleen J., et al.
Publicado: (2023)

Duvelisib, an oral dual PI3K‐δ, γ inhibitor, shows clinical activity in indolent non‐Hodgkin lymphoma in a phase 1 study
por: Flinn, Ian W., et al.
Publicado: (2018)

The Selective Phosphoinoside-3-Kinase p110δ Inhibitor IPI-3063 Potently Suppresses B Cell Survival, Proliferation, and Differentiation
por: Chiu, Honyin, et al.
Publicado: (2017)

Oral PI3K-δ,γ Inhibitor for the Management of People with Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma: A Narrative Review on Duvelisib
por: Shah, Ankit, et al.
Publicado: (2021)

Disease Evolution and Response to Rapamycin in Activated Phosphoinositide 3-Kinase δ Syndrome: The European Society for Immunodeficiencies-Activated Phosphoinositide 3-Kinase δ Syndrome Registry
por: Maccari, Maria Elena, et al.
Publicado: (2018)

Structural, Biochemical, and Biophysical Characterization of Idelalisib Binding to Phosphoinositide 3-Kinase δ
por: Somoza, John R., et al.
Publicado: (2015)

Deconvolution of bulk RNA sequencing in activated phosphoinositide 3‐kinase δ syndrome
por: Huang, Xia, et al.
Publicado: (2023)

Antitumor effects of duvelisib on Epstein–Barr virus‐associated lymphoma cells
por: Kawada, Jun‐ichi, et al.
Publicado: (2018)

Safety and efficacy of dual PI3K-δ, γ inhibitor, duvelisib in patients with relapsed or refractory lymphoid neoplasms: A systematic review and meta-analysis of prospective clinical trials
por: Wang, Zhongwang, et al.
Publicado: (2023)

Occurrence of B-cell lymphomas in patients with Activated Phosphoinositide 3-Kinase δ syndrome
por: Kracker, Sven, et al.
Publicado: (2014)

Distinct roles for phosphoinositide 3-kinases γ and δ in malignant B cell migration
por: Ali, Ahmed Y., et al.
Publicado: (2018)

A T Cell Inflammatory Phenotype is Associated with Autoimmune Toxicity of the PI3K Inhibitor Duvelisib in Chronic Lymphocytic Leukemia
por: Gadi, Deepti, et al.
Publicado: (2022)

Effect of Duvelisib, a Selective PI3K Inhibitor on Seizure Activity in Pentylenetetrazole-Induced Convulsions Animal Model
por: Abdolrahmani, Mahnaz, et al.
Publicado: (2023)

Phosphoinositide 3-kinase δ regulates membrane fission of Golgi carriers for selective cytokine secretion
por: Low, Pei Ching, et al.
Publicado: (2010)

Case Report: First Occurrence of Plasmablastic Lymphoma in Activated Phosphoinositide 3-Kinase δ Syndrome
por: Yin, Zexi, et al.
Publicado: (2021)

Preclinical validation of 3-phosphoinositide-dependent protein kinase 1 inhibition in pancreatic cancer
por: Emmanouilidi, Aikaterini, et al.
Publicado: (2019)

Duvelisib attenuates bleomycin‐induced pulmonary fibrosis via inhibiting the PI3K/Akt/mTOR signalling pathway
por: Li, Xiaohe, et al.
Publicado: (2023)

Deficiency of p110δ Isoform of the Phosphoinositide 3 Kinase Leads to Enhanced Resistance to Leishmania donovani
por: Khadem, Forough, et al.
Publicado: (2014)

Genetic Defects in Phosphoinositide 3-Kinase δ Influence CD8(+) T Cell Survival, Differentiation, and Function
por: Cannons, Jennifer L., et al.
Publicado: (2018)

Airway epithelial phosphoinositide 3-kinase-δ contributes to the modulation of fungi-induced innate immune response
por: Jeong, Jae Seok, et al.
Publicado: (2018)

Cryptotanshinone Reverses Corticosteroid Insensitivity by Inhibition of Phosphoinositide-3-Kinase-δ in Chronic Obstructive Pulmonary Disease
por: Xie, Tao, et al.
Publicado: (2023)

Two cases of successful sirolimus treatment for patients with activated phosphoinositide 3-kinase δ syndrome 1
por: Jiang, Lu, et al.
Publicado: (2023)

HSP90 Inhibition Enhances Antimitotic Drug-Induced Mitotic Arrest and Cell Death in Preclinical Models of Non-Small Cell Lung Cancer
por: O'Connell, Brenda C., et al.
Publicado: (2014)

Genetic or Pharmaceutical Blockade of Phosphoinositide 3-Kinase P110δ Prevents Chronic Rejection of Heart Allografts
por: Ying, Huijun, et al.
Publicado: (2012)

PPARδ Activation Acts Cooperatively with 3-Phosphoinositide-Dependent Protein Kinase-1 to Enhance Mammary Tumorigenesis
por: Pollock, Claire B., et al.
Publicado: (2011)

Phosphoinositide 3-kinase-δ regulates fungus-induced allergic lung inflammation through endoplasmic reticulum stress
por: Lee, Kyung Sun, et al.
Publicado: (2016)

Clinical spectrum and features of activated phosphoinositide 3-kinase δ syndrome: A large patient cohort study
por: Coulter, Tanya I., et al.
Publicado: (2017)

Phosphoinositide 3-Kinase (PI3K) Subunit p110δ Is Essential for Trophoblast Cell Differentiation and Placental Development in Mouse
por: Hu, Xiwen, et al.
Publicado: (2016)

Repeated lipopolysaccharide exposure causes corticosteroid insensitive airway inflammation via activation of phosphoinositide-3-kinase δ pathway
por: Ueda, Keitaro, et al.
Publicado: (2016)

Activated phosphoinositide 3-kinase δ syndrome associated with nephromegaly, growth hormone deficiency, bronchiectasis: a case report
por: Craig, Megan, et al.
Publicado: (2022)

Inhibition of phosphoinositide‑3 kinases γ/δ ameliorates pulmonary granuloma by rescuing Treg function in a sarcoidosis model
por: Zhang, Xian, et al.
Publicado: (2023)

Inhibitors of phosphoinositide 3-kinase (PI3K) and phosphoinositide 3-kinase-related protein kinase family (PIKK)
por: Huang, Xueqin, et al.
Publicado: (2023)

Development and validation of an UPLC-ESI-MS/MS method for quantification of duvelisib in plasma: application to pharmacokinetic study in rats
por: Darwish, Ibrahim A., et al.
Publicado: (2023)

Preclinical Models: Boosting Synergies for Improved Translation
por: Attanasio, Chiara, et al.
Publicado: (2020)

Successful Sirolimus Treatment for Korean Patients with Activated Phosphoinositide 3-kinase δ Syndrome 1: the First Case Series in Korea
por: Kang, Ji-Man, et al.
Publicado: (2020)

NFκB-Mediated Expression of Phosphoinositide 3-Kinase δ Is Critical for Mesenchymal Transition in Retinal Pigment Epithelial Cells
por: Han, Haote, et al.
Publicado: (2023)

Successful haploidentical hematopoietic stem cell transplantation for activated phosphoinositide 3-kinase δ syndrome: Case report and literature review
por: Yang, Xiaolan, et al.
Publicado: (2023)

Author Correction: Phosphoinositide 3-Kinase (PI3K) Subunit p110δ Is Essential for Trophoblast Cell Differentiation and Placental Development in Mouse
por: Hu, Xiwen, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_fnmrpav2kmgfndo5ler642go64